+

WO2000062813A3 - Lipides peg cationiques et méthodes d'utilisation - Google Patents

Lipides peg cationiques et méthodes d'utilisation Download PDF

Info

Publication number
WO2000062813A3
WO2000062813A3 PCT/CA2000/000451 CA0000451W WO0062813A3 WO 2000062813 A3 WO2000062813 A3 WO 2000062813A3 CA 0000451 W CA0000451 W CA 0000451W WO 0062813 A3 WO0062813 A3 WO 0062813A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
cationic
lipids
methods
cpls
Prior art date
Application number
PCT/CA2000/000451
Other languages
English (en)
Other versions
WO2000062813A2 (fr
Inventor
Pieter R Cullis
Tao Chen
David B Fenske
Lorne R Palmer
Kim Wong
Original Assignee
Univ British Columbia
Pieter R Cullis
Tao Chen
David B Fenske
Lorne R Palmer
Kim Wong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Pieter R Cullis, Tao Chen, David B Fenske, Lorne R Palmer, Kim Wong filed Critical Univ British Columbia
Priority to JP2000611949A priority Critical patent/JP5117648B2/ja
Priority to EP00920309A priority patent/EP1173600A2/fr
Priority to AU40962/00A priority patent/AU783647B2/en
Priority to CA002370690A priority patent/CA2370690A1/fr
Publication of WO2000062813A2 publication Critical patent/WO2000062813A2/fr
Priority to EP01927519A priority patent/EP1355670A2/fr
Priority to AU2001254548A priority patent/AU2001254548B2/en
Priority to US09/839,707 priority patent/US7189705B2/en
Priority to AU5454801A priority patent/AU5454801A/xx
Priority to CA002406654A priority patent/CA2406654A1/fr
Priority to JP2001577996A priority patent/JP2004508012A/ja
Priority to PCT/CA2001/000555 priority patent/WO2001080900A2/fr
Publication of WO2000062813A3 publication Critical patent/WO2000062813A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention a trait à des conjugats polymère-lipide-cationique (CPL) tel que des conjugats poly(éthylène glycol)-lipide-cationique distaux pouvant être incorporés à des liposomes classiques ou à des liposomes furtifs ou à toute autre formulation à base de lipide pour renforcer l'absorption cellulaire. Les CPL selon l'invention comportent une fraction lipidique, un polymère hydrophile et une fraction polycationique. L'invention concerne également une méthode permettant de renforcer la libération intracellulaire d'acides nucléiques.
PCT/CA2000/000451 1999-04-20 2000-04-20 Lipides peg cationiques et méthodes d'utilisation WO2000062813A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2000611949A JP5117648B2 (ja) 1999-04-20 2000-04-20 カチオン性ｐｅｇ脂質および使用方法。
EP00920309A EP1173600A2 (fr) 1999-04-20 2000-04-20 Lipides peg cationiques et m thodes d'utilisation
AU40962/00A AU783647B2 (en) 1999-04-20 2000-04-20 Cationic peg-lipids and methods of use
CA002370690A CA2370690A1 (fr) 1999-04-20 2000-04-20 Lipides peg cationiques et methodes d'utilisation
PCT/CA2001/000555 WO2001080900A2 (fr) 2000-04-20 2001-04-20 Procedes permettant d'ameliorer la transfection a mediation splp (particule plasmide-lipide stabilisee) au moyen de destabilisateurs de la membrane endosomale
EP01927519A EP1355670A2 (fr) 2000-04-20 2001-04-20 Procedes permettant d'ameliorer la transfection a mediation splp (particule plasmide-lipide stabilisee) au moyen de destabilisateurs de la membrane endosomale
AU2001254548A AU2001254548B2 (en) 2000-04-20 2001-04-20 Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
US09/839,707 US7189705B2 (en) 2000-04-20 2001-04-20 Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
AU5454801A AU5454801A (en) 2000-04-20 2001-04-20 Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers
CA002406654A CA2406654A1 (fr) 2000-04-20 2001-04-20 Procedes permettant d'ameliorer la transfection a mediation splp (particule plasmide-lipide stabilisee) au moyen de destabilisateurs de la membrane endosomale
JP2001577996A JP2004508012A (ja) 2000-04-20 2001-04-20 エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13015199P 1999-04-20 1999-04-20
US60/130,151 1999-04-20

Publications (2)

Publication Number Publication Date
WO2000062813A2 WO2000062813A2 (fr) 2000-10-26
WO2000062813A3 true WO2000062813A3 (fr) 2001-08-09

Family

ID=22443303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000451 WO2000062813A2 (fr) 1999-04-20 2000-04-20 Lipides peg cationiques et méthodes d'utilisation

Country Status (5)

Country Link
EP (1) EP1173600A2 (fr)
JP (2) JP5117648B2 (fr)
AU (1) AU783647B2 (fr)
CA (1) CA2370690A1 (fr)
WO (1) WO2000062813A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4656675B2 (ja) 1997-05-14 2011-03-23 ユニバーシティー オブ ブリティッシュ コロンビア 脂質小胞への荷電した治療剤の高率封入
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
AU5454801A (en) * 2000-04-20 2001-11-07 Univ British Columbia Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers
EP1328254B1 (fr) * 2000-10-25 2007-02-21 The University Of British Columbia Formulations de lipides pour une administration ciblee
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
ES2354607T3 (es) 2002-06-28 2011-03-16 Protiva Biotherapeutics Inc. Procedimiento y aparato para producir liposomas.
WO2004082626A2 (fr) * 2003-03-18 2004-09-30 Ethicon, Inc. Diagnostic et traitement faisant appel a un inhibiteur de l'aromatase
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
CA2551022C (fr) * 2003-09-15 2013-06-04 Protiva Biotherapeutics, Inc. Composes conjugues lipidiques polyethyleneglycol-dialkyloxypropyle et utilisations de ces composes
FR2870741B1 (fr) 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
ATE536418T1 (de) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc Lipidverkapselte interferenz-rna
WO2007028341A1 (fr) * 2005-09-09 2007-03-15 Beijing Diacrid Medical Technology Co., Ltd. Nanomicelles servant de medicaments anticancereux a polyethylene phospholipides glycolyles contenant des vinca alcaloides
JP5336853B2 (ja) 2005-11-02 2013-11-06 プロチバ バイオセラピューティクス インコーポレイティッド 修飾ｓｉＲＮＡ分子およびその使用法
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2710713C (fr) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencage de l'expression de la polo-like kinase a l'aide d'un arn interferent
EP2281041B1 (fr) 2008-04-15 2014-07-02 Protiva Biotherapeutics Inc. Réduction au silence de l'expression du gène csn5 au moyen d'arn interférant
PT2279254T (pt) 2008-04-15 2017-09-04 Protiva Biotherapeutics Inc Novas formulações lipídicas para entrega de ácido nucleico
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2011000107A1 (fr) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Formulations lipidiques inédites permettant l'administration d'agents thérapeutiques en direction de tumeurs solides
WO2011000106A1 (fr) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Lipides cationiques et procédés améliorés pour l'administration d'agents thérapeutiques
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
CA2775092A1 (fr) 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions et procedes pour reduire au silence des genes exprimes dans le cancer
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
WO2011141704A1 (fr) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Nouveaux lipides cationiques cycliques et procédés d'utilisation
EP2569276B1 (fr) 2010-05-12 2021-02-24 Arbutus Biopharma Corporation Nouveaux lipides cationiques et procédés d'utilisation de ceux-ci
CA2802994A1 (fr) 2010-06-17 2011-12-22 The United States Of America As Represented By The Secretary, National I Nstitutes Of Health Compositions et procedes pour traiter des affections inflammatoires
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012170930A1 (fr) 2011-06-08 2012-12-13 Shire Human Genetic Therapies, Inc Compositions de nanoparticules lipides et procédés pour le transfert d'arnm
US11073451B2 (en) 2011-12-19 2021-07-27 Kode Biotech Limited Biocompatible method of functionalising substrates with inert surfaces
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP2817287B1 (fr) 2012-02-24 2018-10-03 Arbutus Biopharma Corporation Lipides cationiques trialkylés et leurs procédés d'utilisation
KR20200036033A (ko) * 2012-03-16 2020-04-06 메르크 파텐트 게엠베하 표적화 아미노산 지질
EP2859102A4 (fr) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Polynucléotides résistant à la nucléase et leurs utilisations
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
WO2014047533A1 (fr) 2012-09-21 2014-03-27 Frank Bedu-Addo Compositions de vaccins perfectionnées et méthodes d'utilisation
EP3446712A1 (fr) 2013-03-14 2019-02-27 Translate Bio Ma, Inc. Compositions d'arnm cftr et procédés et utilisations associés
JP6586075B2 (ja) 2013-03-14 2019-10-02 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
US20160151284A1 (en) 2013-07-23 2016-06-02 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
EA201992208A1 (ru) 2013-10-22 2020-07-31 Транслейт Био, Инк. ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
CA2928188A1 (fr) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Therapie arnm pour deficience en argininosuccinate synthetase
SG11201608725YA (en) 2014-04-25 2016-11-29 Shire Human Genetic Therapies Methods for purification of messenger rna
US10415037B2 (en) 2014-10-02 2019-09-17 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis B virus gene expression
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
US20180208932A1 (en) 2015-07-29 2018-07-26 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis b virus gene expression
BR112018003784A2 (pt) 2015-08-24 2018-09-25 Halo-Bio Rnai Therapeutics, Inc. nanopartículas de polinucleotídeo para a modulação da expressão gênica e sua utilização
CA3005251A1 (fr) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipides en tant que vecteurs synthetiques pour ameliorer le traitement et la presentation de l'antigene ex-vivo en therapie cellulaire dendritique
US11191849B2 (en) 2016-06-30 2021-12-07 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
CA3063531A1 (fr) 2017-05-16 2018-11-22 Translate Bio, Inc. Traitement de la fibrose kystique par administration d'arnm a codons optimises codant pour la cftr
EP3841208A1 (fr) 2018-08-24 2021-06-30 Translate Bio, Inc. Procédés de purification d'arn messager
EP3883592A1 (fr) 2018-11-21 2021-09-29 Translate Bio, Inc. Traitement de la fibrose kystique par administration d'arnm nébulisé codant pour la cftr
GB201910299D0 (en) 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses
CA3162374A1 (fr) * 2019-12-20 2021-06-24 So Jin Lee Kit de preparation de composition de nanoparticules servant a l'administration de medicament, comprenant un sel d'acide polylactique
JP2023518944A (ja) 2020-03-17 2023-05-09 ジェネヴァント サイエンシズ ゲーエムベーハー 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
JP2023553343A (ja) 2020-11-25 2023-12-21 アカゲラ・メディスンズ，インコーポレイテッド 核酸を送達するための脂質ナノ粒子および関連する使用方法
WO2023144798A1 (fr) 2022-01-31 2023-08-03 Genevant Sciences Gmbh Lipides cationiques ionisables pour nanoparticules lipidiques
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024214632A1 (fr) * 2023-04-14 2024-10-17 国立大学法人 東京大学 Polymère cationique contenant un groupe phosphonium, et particules polymères et composition pharmaceutique le contenant
WO2025052278A1 (fr) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Lipides cationiques à base de pyrrolidine pour administration de nanoparticules lipidiques d'agents thérapeutiques à des cellules stellaires hépatiques

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016202A2 (fr) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Composition a base de liposomes fusogenes et procede correspondant
WO1998046208A1 (fr) * 1997-04-17 1998-10-22 The Regents Of The University Of Michigan Systeme de delivrance d'adn de follicule pileux
WO1998051285A2 (fr) * 1997-05-15 1998-11-19 Genzyme Corporation Formulations amphiphiles cationiques
WO1999005303A1 (fr) * 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Preparation de particules de lipides-acides nucleiques grace a un procede d'extraction par solvant et d'hydratation directe
WO1999005094A1 (fr) * 1997-07-23 1999-02-04 Ribozyme Pharmaceuticals, Incorporated Nouvelles compositions d'administration de molecules chargees negativement
WO1999065461A2 (fr) * 1998-06-19 1999-12-23 Genzyme Corporation Complexes micellaires d'amphiphiles cationiques
WO2000043043A1 (fr) * 1999-01-21 2000-07-27 Georgetown University Lipoplexe et polyplexe stabilises selon un procede de post-application d'un ligand-peg dans l'administration ciblee de genes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69632401T2 (de) * 1995-06-07 2005-05-19 Imarx Pharmaceutical Corp., Tucson Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
EP0932390A1 (fr) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Composition de liposomes therapeutiques et procede
EP1046394A3 (fr) * 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Nouvelles compositions utilisables pour la délivrance de composés dans une cellule
ATE374785T1 (de) * 2000-03-02 2007-10-15 Mitsubishi Pharma Corp Gpib-gebundenes konstrukt und verwendungen davon

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016202A2 (fr) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Composition a base de liposomes fusogenes et procede correspondant
WO1998046208A1 (fr) * 1997-04-17 1998-10-22 The Regents Of The University Of Michigan Systeme de delivrance d'adn de follicule pileux
WO1998051285A2 (fr) * 1997-05-15 1998-11-19 Genzyme Corporation Formulations amphiphiles cationiques
WO1999005094A1 (fr) * 1997-07-23 1999-02-04 Ribozyme Pharmaceuticals, Incorporated Nouvelles compositions d'administration de molecules chargees negativement
WO1999005303A1 (fr) * 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Preparation de particules de lipides-acides nucleiques grace a un procede d'extraction par solvant et d'hydratation directe
WO1999065461A2 (fr) * 1998-06-19 1999-12-23 Genzyme Corporation Complexes micellaires d'amphiphiles cationiques
WO2000043043A1 (fr) * 1999-01-21 2000-07-27 Georgetown University Lipoplexe et polyplexe stabilises selon un procede de post-application d'un ligand-peg dans l'administration ciblee de genes

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ANWER K ET AL: "OPTIMIZATION OF CATIONIC LIPID/DNA COMPLEXES FOR SYSTEMIC GENE TRANSFER TO TUMOR LESIONS", JOURNAL OF DRUG TARGETING,HARWOOD ACADEMIC PUBLISHERS GMBH,DE, vol. 8, no. 2, 2000, pages 125 - 135, XP000951678, ISSN: 1061-186X *
ARUNA NATHAN ET AL: "COPOLYMERS OF LYSINE AND POLYETHYLENE GLYCOL: A NEW FAMILY OF FUNCTIONALIZED DRUG CARRIERS", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 4, no. 1, 1993, pages 54 - 62, XP000336592, ISSN: 1043-1802 *
BHATTACHARYA S V ET AL: "Synthesis of novel cationic lipids with oxyethylene spacers at the linkages between hydrocarbon chains and pseudoglyceryl backbone", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 40, no. 46, 12 November 1999 (1999-11-12), pages 8167 - 8171, XP004180445, ISSN: 0040-4039 *
CHEN TAO ET AL: "Fluorescent-labeled poly(ethylene glycol) lipid conjugates with distal cationic headgroups.", BIOCONJUGATE CHEMISTRY, vol. 11, no. 3, May 2000 (2000-05-01), pages 433 - 437, XP002157295, ISSN: 1043-1802, Retrieved from the Internet <URL:http://pubs.acs.org/CHECKCCIP-979559877/isubscribe/journals/bcches/asap/pdf/bc990171x.pdf> [retrieved on 20000330] *
HASELGRUBLER T ET AL: "SYNTHESIS AND APPLICATIONS OF A NEW POLY(ETHYLENE GLYCOL) DERIVATIVE FOR THE CROSSLINKING OF AMINES WITH THIOLS", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 6, no. 3, 1 May 1995 (1995-05-01), pages 242 - 248, XP000505483, ISSN: 1043-1802 *
JAGUR-GRODZINSKI J: "Biomedical application of functional polymers", REACTIVE & FUNCTIONAL POLYMERS,NL,ELSEVIER SCIENCE PUBLISHERS BV, vol. 39, no. 2, 15 February 1999 (1999-02-15), pages 99 - 138, XP004160680, ISSN: 1381-5148 *
MACIAN M ET AL: "Preliminary studies of the toxic effects of non-ionic surfactants derived from lysine.", TOXICOLOGY, JAN 8 1996, VOL. 106, NO. 1-3, PAGE(S) 1-9, XP000978704 *
MORI A ET AL: "STABILIZATION AND REGULATED FUSION OF LIPOSOMES CONTAINING A CATIONIC LIPID USING AMPHIPATHIC POLYETHYLENEGLYCOL DERIVATIVES", JOURNAL OF LIPOSOME RESEARCH,US,MARCEL DEKKER, NEW YORK, vol. 8, no. 2, 1 May 1998 (1998-05-01), pages 195 - 211, XP000752693, ISSN: 0898-2104 *
See also references of EP1173600A2 *
TRUBETSKOY V S ET AL: "NEW APPROACHES IN THE CHEMICAL DESIGN OF GD-CONTAINING LIPOSOMES FOR USE IN MAGNETIC RESONANCE IMAGING OF LYMPH NODES", JOURNAL OF LIPOSOME RESEARCH,US,MARCEL DEKKER, NEW YORK, vol. 4, no. 2, 1994, pages 961 - 980, XP000619021, ISSN: 0898-2104 *
TRUBETSKOY V.S. ET AL: "New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes", JOURNAL OF LIPOSOME RESEARCH, 1994, VOL. 4, NO. 2, PAGE(S) 961-983, XP000978705 *
VESKA TONCHEVAL ET AL: "BLOCK COPOLYMERS WITH pH-DEPENDENT SECONDARYSTRUCTURE", JOURNAL OF CONTROLLED RELEASE, vol. 48, no. 2 - 3, October 1997 (1997-10-01), pages 301 - 302, XP002157296, ISSN: 0168-3659 *
WEISSIG V ET AL: "Long-circulating gadolinium-loaded liposomes: potential use for magnetic resonance imaging of the blood pool", COLLOIDS AND SURFACES B (BIOINTERFACES), OCT. 2000, ELSEVIER, NETHERLANDS, vol. 18, no. 3-4, pages 293 - 299, XP000971876, ISSN: 0927-7765 *
ZALIPSKY S ET AL: "LONG CIRCULATING, CATIONIC LIPOSOMES CONTAINING AMINO-PEG-PHOSPHATIDYLETHANOLAMINE", FEBS LETTERS,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM,NL, vol. 353, 1994, pages 71 - 74, XP002920144, ISSN: 0014-5793 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents

Also Published As

Publication number Publication date
WO2000062813A2 (fr) 2000-10-26
AU4096200A (en) 2000-11-02
JP2012122075A (ja) 2012-06-28
JP5117648B2 (ja) 2013-01-16
JP2002542341A (ja) 2002-12-10
AU783647B2 (en) 2005-11-17
EP1173600A2 (fr) 2002-01-23
CA2370690A1 (fr) 2000-10-26

Similar Documents

Publication Publication Date Title
WO2000062813A3 (fr) Lipides peg cationiques et méthodes d&#39;utilisation
WO2003103822A3 (fr) Nanocapsules lipidiques indetectables, procedes de preparation de celles-ci et utilisation de ces nanocapsules en tant que support de principe(s) actif(s)
WO2003068144A3 (fr) Agents cytotoxiques supportant une fraction reactive de polyethyleneglycol, conjugues cytotoxiques comprenant des groupes de liaison de polyethyleneglycol et leurs procedes de fabrication et d&#39;utilisation
FR2840532B1 (fr) Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)
WO2000061543A3 (fr) Esters de l-carnitine ou de l-carnitines alcanoyles utilises comme lipides cationiques pour un apport intracellulaire de composes actifs d&#39;un point de vue pharmacologique
WO2000065024A3 (fr) Micelles polymeriques hyperramifiees destinees a encapsuler et transporter des molecules hydrophobes
WO2001062299A3 (fr) Conjugues polymeres hydrosolubles d&#39;acide artelinique
WO2002034236A3 (fr) Formulations de lipides pour une administration ciblee
WO2003000233A3 (fr) Liberation de petites molecules hydrophiles comprises dans des vesicules lipidiques
CA2393638A1 (fr) Procede de preparation d&#39;esters de 1-benzotriazolyl carbonate de poly(ethylene glycol)
AU1928501A (en) Formulations for pharmaceutical agents ionizable as free acids or free bases
CA2270396A1 (fr) Reactifs cationiques pour transfection
WO2002097116A3 (fr) Systeme de delivrance d&#39;acides nucleiques
WO2002038105A3 (fr) Nouveaux conjugues d&#39;acide amine et d&#39;analogues de polyamine utiles en tant qu&#39;agents anticancer
CA2252055A1 (fr) Liposomes entrainant une fusion
CA2196780A1 (fr) Systeme d&#39;administration liposomique comprenant des lipopolyamines cationiques et des lipides neutres pour l&#39;administration d&#39;agents biologiquements actifs
MXPA02012068A (es) Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa.
WO2003045306A3 (fr) Composes phenoxy amine et compositions pour administrer des principes actifs
WO2002036161A3 (fr) Nouvelles compositions ciblees a usage diagnostique ou therapeutique
AU2102101A (en) Use of cationic lipids for intracellular protein delivery
WO2007002886A3 (fr) Compositions et procedes pour l&#39;obtention de complexes proteines-lipides moins immunogenes
EP1068306A4 (fr) Derives de lipides de pentaerythritol
EP2452684A3 (fr) Micelles
WO2022226008A3 (fr) Lipides cationiques et compositions de ceux-ci
WO2004105697A3 (fr) Lipides pour la transfection d&#39;acides nucleiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2370690

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

Ref document number: 2000 611949

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000920309

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000920309

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载